Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Stockmann’s Interim report for January–September 2021 will be published as an Interim Management Statement

STOCKMANN plc, Other information disclosed according to the rules of the Exchange 22.10.2021 at 11.00 EETStockmann plc will publish its Interim report for January–September 2021 as a shorter Interim Management Statement. The publishing date and time will remain the same, 29 October 2021 at 8:00.The press and analyst briefing will be held on 29 October 2021 at 10:00 as a live webcast, that can be followed by this link  or on the address stockmanngroup.com.  The recording and presentation material

Invitation to Pexip Capital Markets Day

(Oslo, Norway, October 22, 2021) Pexip Holding ASA (“Pexip”, Oslo Børs Ticker: PEXIP) invites investors, analysts, media and other stakeholders to a Capital Markets Day (CMD) on Thursday December 9 2021, from 09:00 to 11:30 CET. The event will take place at Oslo Konserthus (Lille Sal), Munkedamsveien 14, Oslo, Norway, and a live webcast of the event will also be streamed via https://investor.pexip.comEvent details for the Pexip Capital Markets Day 2021 Date: December 9, 2021 Time: 09:00 - 11:30 CET For registration to the event, please follow this link and select either in-person

BioStock: Targinta’s CEO on TARG10 and the spin-off

Targinta has selected its first drug candidate TARG10, which shows an inhibitory effect on tumour growth and reduced metastasis in triple-negative breast cancer. In addition, the company is in an intensive phase where it is preparing for a spin-off from the parent company Xintela. BioStock contacted Targinta’s CEO Per Norlén to learn more about TARG10 and the spin-off.Read the interview with Targinta's CEO Per Norlén at biostock.se: https://www.biostock.se/en/2021/10/targintas-ceo-on-targ10-and-the-spin-off/ This is a press release from BioStock - Connecting Innovation & Capital.

Nepa AB appoints Nomination Committee

STOCKHOLM, Sweden - Nepa, a leading consumer research and analytics company, providing insight solutions to strengthen brands and drive sales by increased marketing effectiveness, has had a Nomination Committee appointed for the company. Nepa AB’s four largest shareholders on September 30, 2021, have in consultation with the Chairman of the Board, Katarina Bonde, appointed the following representatives to serve on the Nomination Committee: - Ulrich Boyer, private investor - Marcus Wahlberg, representing Elementa - Ulrik Grönvall, representing Swedbank Robur - Niclas Öhman,

Irisity wins €0.5m SaaS contract to protect sites across the Netherlands.

Irisity AB (publ): In partnership with Spyke Security Irisity delivers video analytics technology to customers in the Netherlands, with an estimated order value of EUR 0.5 million. Due to the confidential nature of this relationship, and the security applications involved, we are unable to disclose any further details regarding end customers identity or the specifics of the projects. For further information: Andreas Höye, Irisity IR Phone: +46 769 01 34 51 E-mail: andreas.hoye@irisity.com

Publishing of Apetit Plc’s Business Review for January-September 2021

Apetit Plc, Press release, on 22 October 2021 at 10:00 a.m.Apetit Plc will publish its Business Review for January-September 2021 on Friday 29 October 2021 at 8.30 a.m. A separate press conference in relation to the Business Review will not be arranged.Apetit PlcFor further information, please contact:Sanna Väisänen, Director, Corporate Communications and Sustainability, tel. +358 10 402 4041Apetit is a food industry company firmly rooted in Finnish primary production. Our operations are based on a unique and sustainable value chain: we create well-being with vegetables by offering

Restructuring programme of Componenta Castings Ltd has ended

Componenta Corporation Stock Exchange Release, 22 October 2021 at 10:00 EEST The restructuring programme of Componenta Castings Ltd has ended upon the approval of the payment of restructuring debt carried out by the company on 15 October 2021 by the supervisor and the provision of the supervisor’s final account of the restructuring programme to creditors today on 22 October 2021. The Board of Directors of Componenta Corporation has on 13 October 2021 decided to end Componenta Castings Ltd’s (“Componenta Castings”) restructuring programme prematurely. Componenta Castings had previously

Introducing Virtual Lapland: a new way to experience the northern Finnish nature

Explore and enjoy a 3D Arctic environment by Only in LaplandVirtual Lapland is a breathtaking, free VR experience by Only in Lapland, enabling people around the world to immerse themselves in the seasons and sensations of the north. The fully computer-generated environment is a virtual representation of the last wilderness in Europe and offers interactive elements, information, and stories about Lapland, including an animated tale about the Northern Lights. Finnish Lapland's official travel channel, Only in Lapland teamed up with Zoan, the studio behind other popular virtual destinations,

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Gothenburg, October 22, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that it has appointed professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor to the company.Dr. Gunilla Enblad is a Senior Consultant in Oncology since 2000 and was Head of Department at the Oncology Clinic at Uppsala University Hospital between 2004 and 2012. Enblad is Professor in Oncology at Uppsala University

DanCann Pharma A/S: Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency

COPENHAGEN, Denmark, 22 October 2022, DanCann Pharma A/S ("DanCann Pharma"), a Danish company powered by cannabinoids, hereby on behalf of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”), announce that Tetra Bio-Pharma - a leader in cannabinoid-derived drug discovery and development – yesterday announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the Company's application for Orphan Drug Designation (ODD) for its investigational medicine QIXLEEF™ as a potential treatment for Complex Regional Pain Syndrome (CRPS), a

BioStock: Ultimovacs receives dual FDA Fast Track for UV1

Ultimovacs’ mission to develop a cancer vaccine just received a significant boost. The FDA has granted dual Fast Track designation for the company’s candidate UV1 as an add-on therapy to checkpoint inhibitors in advanced malignant melanoma patients. The designation potentially provides expedited review of UV1 for approval.Read the article at biostock.se : https://www.biostock.se/en/2021/10/ultimovacs-receives-dual-fda-fast-track-for-uv1/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Yoav Ben-Eli has been nominated as CEO of Crown Energy

On September 15, 2021 Crown Energy AB(publ) (“Crown Energy”) has announced that Yoav Ben-Eli was appointed as CEO of Crown Energy, subject to an exemption from the residency requirement for the CEO, as stipulated in Chapter 8, Section 30 in the Swedish Companies Act (2005:551), at the Swedish Companies Registration Office (Sw.Bolagsverket). The exemption from the residency requirement has been confirmed by SCRO and Yoav Ben-Eli will now assume position as the CEO, and that Andreas Forssell is resume as the company’s deputy CEO

I-Tech AB (publ) Interim report Q3 2021

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the third quarter 2021 Click here on the 22 October 2021 at 11:00 to follow the webcast Summary of the period ” Positive result with a strong contribution from a growing customer base ” · Net turnover for the period amounted to 13 811 (11 956) kSEK, corresponding to an increase in turnover of 16% (-2%). Operating profit/loss amounted to 837 (-723) kSEK. July to September 2021 · No important events occurred during the period. Important events after the period

INVITATION: INVISIO invites you to a conference call October 29 at 10:00 CEST

INVISIO is pleased to invite press, investors and analysts to a conference call on October 29 at 10.00 CEST where CEO Lars Højgård Hansen will present the Interim Report January – September 2021.The conference call, which will be held in English, will begin with a presentation of the report followed by a Q&A session. The Interim Report January – September 2021 will be published on October 28, 2021, at 14:00 CEST.Phone number for the conference:To participate in the conference call, use the dial-in numbers below. Please dial in 5-10 minutes prior to the scheduled start time in order to

Moberg Pharma’s nomination committee appointed

STOCKHOLM, October 22[nd], 2021 – In accordance with the resolution of the Annual General Meeting on May 18[th], 2021, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group of

Lipum and the Scientific Advisory Board meet for the annual workshop

News: Umeå, 22 October 2021. Next week Lipums (publ) annual workshop with the Scientific Advisory Board will take place in Stockholm. The Scientific Advisory Board of Lipum constitute an invaluable resource of experience from academic research to clinical practice within the field chronic inflammatory diseases. The members contributions are expressed in specific advices along Lipums development, as well as the sharing of deep knowledge in more strategic discussions. An important forum has been the annual workshop with the Lipum team. Reflecting the progress this year’s workshop

BoMill announces a change in the Board of Directors

BoMill AB (“BoMill” or the “Company”) hereby announces that the company’s largest shareholder Capagro SAS (“Capagro”) onwards will be represented in the Board of Directors through Pierre Kiener as co-opted member and Tom Espiard-Cignaco as observer, until the next Annual General Meeting taking place in 2022, before June 30[th]. The current representative from Capagro in BoMill’s Board of Directors, Julie Peyrache, will leave Capagro for assignments outside of the group on October 22[nd], and will hence therefore also leave BoMill’s Board of Directors. The resignation of Julie Peyrache from

K-Fast Holding AB’s Nomination committee for the 2022 Annual General Meeting

The Nomination committee for the 2022 Annual General Meeting of K-Fast Holding AB (publ) has been appointed.According to the instructions for the Nomination committee adopted at K-Fast Holding AB (publ)’s Extraordinary General Meeting on 19 August 2019, the Nomination committee shall consist of four members representing the three largest shareholders in terms of number of votes as of 30 September, together with the Chairman of the Board. If a shareholder, who is entitled to appoint a representative to the Nomination committee, abstains from appointing a representative, the right to appoint

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 21st October 2021, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 26,016,081 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Crown Energy & Proger Spa have mutually agreed to terminate Proger’s advisory agreement with Crown Energy, entered in 2017

Crown Energy AB (publ) (“Crown Energy” or “Company”) announces that Crown Energy and Proger Spa. have mutually decided to end their advisory relationship and terminate the advisory service agreement, entered in 2017.Proger Spa, have been employed by Crown Energy as technical, operational, legal and safety advisor, for developing and creating the conditions for the exploitation of the rights of Crown Energy in respect of a Production Sharing Agreement contract relating to the Salah Ad Din region in Iraq. Crown Energy and Yoav Ben-Eli would like to thank Proger Spa. for their continuous

IRRAS Announces Collaboration with Aarhus University to Develop Software that Calculates Brain Compliance using its IRRAflow System

· As part of their established collaboration agreement, IRRAS, Aarhus University, and Aarhus University Hospital will collectively work to quantify brain compliance using the company’s IRRAflow system. · The combination of compliance calculations and IRRAflow treatment may provide real-time data that determines effectiveness and completion of therapeutic treatment.Stockholm, October 22, 2021 - IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the initial project from its previously announced

Interim Report January-September 2021 – Pricer AB (publ)

High delivery activity despite challenges in supply and logistics chains  Third quarter 2021 · Net sales amounted to SEK 496.0 M (565.7), a decrease of 12 percent compared to the same period last year. · Operating profit amounted to SEK 40.1 M (75.1), which corresponds to an operating margin of 8.1 percent (13.3). · Order intake was SEK 307 M (440), a decrease of 30 percent compared to the same period last year. · Order backlog amounted to SEK 396 M (754), of which the majority is expected to be delivered in Q4 2021. · Profit for the period was SEK 32.0 M (69.3). ·

Heliospectra (publ) Interim Report July - September 2021

(Gothenburg, Sweden, October 22, 2021, at 08:30 CEST)– Heliospectra AB (publ (Nasdaq First North Growth Market: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents its’ Interim Report for July - September 2021.Full report is enclosed to this press release and is also uploaded at https://www.heliospectra.com/investor-relations/investor-relations. SUMMARY OF REPORT: Sales And Financial Performance for the period July - September and January – September Order intake during the period July - September amounted to

235% higher operating profit during strong growth (interim report quarter three 2021)

Third Quarter (July–Sep 2021)     · Net sales amounted to TSEK 75,938 (47,411), which is an increase by 60,2% compared to the same period last year. · The gross margin amounted to 60.2% (58.1). · Operating profit before depreciation and amortization (EBITDA) amounted to TSEK 20,082 (7,979), which corresponds to an operating margin before depreciation and amortization of 26.4% (16.8). · Operating profit (EBIT) amounted to TSEK 12,736 (3,795), which corresponds to an operating margin of 16.8% (8.0). · Earnings per share before dilution amounted to SEK 0.92 (0.35) (

There are no items matching the current filter
There are no more items matching the current filter
Back to top